Aurinia Pharmaceuticals Inc
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AUPH Company Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
AUPH Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AUPH Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AUPH by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AUPH's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of AUPH in WallStreetBets Daily Discussion
AUPH News
Recent insights relating to AUPH
CNBC Recommendations
Recent picks made for AUPH stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AUPH
Corporate Flights
Flights by private jets registered to AUPH
Our Analysis